Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Engerix-B Booster for HBIG Production
NCT01311674Phase 3Terminated
- Sponsor
- Emergent BioSolutions
- Start
- Sep 2009
- Primary completion
- Mar 2011
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Hepatitis B vaccine in hepatitis B (HBV) (2 arms), sponsored by Emergent BioSolutions. Primary endpoint: Anti-HBs Antibody Titers AUC(0-t). Started Sep 2009; status: terminated.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT01311674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01311674.